(Q42991834)

12 November 2017

A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. (English)

1 reference

12 November 2017

3

Astemborski J

1 reference

12 November 2017

6

Vlahov D

1 reference

12 November 2017

5

Nelson KE

1 reference

12 November 2017

7

Thomas DL

1 reference

12 November 2017

Inglesby TV

1

1 reference

12 November 2017

Rai R

series ordinal

2

1 reference

12 November 2017

Gruskin L

series ordinal

4

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

12 November 2017

1 reference

12 November 2017

29

1 reference

12 November 2017

2

1 reference

12 November 2017

590-596

1 reference

Epidemiology of hepatitis C

12 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Natural history of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Dose-finding study of interferon alfa-n3 in hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Management of hepatitis C: a national survey of gastroenterologists and hepatologists

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Correlates of hepatitis C virus infections among injection drug users.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Attributable risk for symptomatic liver cirrhosis in Italy. Collaborative Groups for the Study of Liver Diseases in Italy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Hepatitis C and alcohol

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Essential roles of the Fas ligand in the development of hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290219

7 January 2021

Identifiers

DOI

10.1002/HEP.510290219

1 reference

12 November 2017

1 reference